Level of systolic blood pressure within the normal range and risk of recurrent stroke.

CONTEXT Recurrent stroke prevention guidelines suggest that larger reductions in systolic blood pressure (SBP) are positively associated with a greater reduction in the risk of recurrent stroke and define an SBP level of less than 120 mm Hg as normal. However, the association of SBP maintained at such levels with risk of vascular events after a recent ischemic stroke is unclear. OBJECTIVE To assess the association of maintaining low-normal vs high-normal SBP levels with risk of recurrent stroke. DESIGN, SETTING, AND PATIENTS Post hoc observational analysis of a multicenter trial involving 20,330 patients (age ≥50 years) with recent non-cardioembolic ischemic stroke; patients were recruited from 695 centers in 35 countries from September 2003 through July 2006 and followed up for 2.5 years (follow-up ended on February 8, 2008). Patients were categorized based on their mean SBP level: very low-normal (<120 mm Hg), low-normal (120-<130 mm Hg), high-normal (130-<140 mm Hg), high (140-<150 mm Hg), and very high (≥150 mm Hg). MAIN OUTCOME MEASURES The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. RESULTS The recurrent stroke rates were 8.0% (95% CI, 6.8%-9.2%) for the very low-normal SBP level group, 7.2% (95% CI, 6.4%-8.0%) for the low-normal SBP group, 6.8% (95% CI, 6.1%-7.4%) for the high-normal SBP group, 8.7% (95% CI, 7.9%-9.5%) for the high SBP group, and 14.1% (95% CI, 13.0%-15.2%) for the very high SBP group. Compared with patients in the high-normal SBP group, the risk of the primary outcome was higher for patients in the very low-normal SBP group (adjusted hazard ratio [AHR], 1.29; 95% CI, 1.07-1.56), in the high SBP group (AHR, 1.23; 95% CI, 1.07-1.41), and in the very high SBP group (AHR, 2.08; 95% CI, 1.83-2.37). Compared with patients in the high-normal SBP group, the risk of secondary outcome was higher for patients in the very low-normal SBP group (AHR, 1.31; 95% CI, 1.13-1.52), in the low-normal SBP group (AHR, 1.16; 95% CI, 1.03-1.31), in the high SBP group (AHR, 1.24; 95% CI, 1.11-1.39), and in the very high SBP group (AHR, 1.94; 95% CI, 1.74-2.16). CONCLUSION Among patients with recent non-cardioembolic ischemic stroke, SBP levels during follow-up in the very low-normal (<120 mm Hg), high (140-<150 mm Hg), or very high (≥150 mm Hg) range were associated with increased risk of recurrent stroke. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00153062.

[1]  D. Levy,et al.  Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 1999, Hypertension.

[2]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[3]  H. Black,et al.  Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. , 2000, Hypertension.

[4]  P. Sandercock,et al.  Blood Pressure and Clinical Outcomes in the International Stroke Trial , 2002, Stroke.

[5]  L. Guize,et al.  Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. , 2002, Archives of internal medicine.

[6]  Roberto Pastor-Barriuso,et al.  Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure: An Evaluation of Their Joint Effect on Mortality , 2003, Annals of Internal Medicine.

[7]  ParveenRashid,et al.  Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events , 2003 .

[8]  J. Leonardi-Bee,et al.  Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review , 2003, Stroke.

[9]  M. Caldwell,et al.  American Heart Association: Council on Cardiovascular Nursing , 2004, The Journal of cardiovascular nursing.

[10]  H. Diener,et al.  Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES) , 2005, Stroke.

[11]  J. Rouleau,et al.  Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. , 2005, Journal of the American Society of Nephrology : JASN.

[12]  V. Chair,et al.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the , 2006, Circulation.

[13]  M. Woodward,et al.  Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial , 2006, Journal of hypertension.

[14]  D. Sica.  Hypertension treatment: how important is consistency of effect? , 2007, Hypertension.

[15]  Gina Soriya,et al.  Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? , 2007 .

[16]  M. Glickman,et al.  Blood Pressure and Survival in the Oldest Old , 2007, Journal of the American Geriatrics Society.

[17]  W. Elliott.  Association Between Blood Pressure and Survival over 9 Years in a General Population Aged 85 and Older , 2007 .

[18]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[19]  S. Yusuf,et al.  Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study , 2009, Journal of hypertension.

[20]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[21]  W. Elliott.  Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events , 2009 .

[22]  A. Rabinstein.  Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke , 2009 .

[23]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[24]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[25]  G. Chrysant,et al.  Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. , 2010, The American journal of cardiology.

[26]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[27]  D. Jatužis,et al.  The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial , 2011, The Lancet.

[28]  S. Bangalore,et al.  Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials , 2011, Circulation.

[29]  G. Mancia,et al.  Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients , 2011, Journal of hypertension.

[30]  Irene Katzan,et al.  Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. , 2011, Stroke.

[31]  W. Elliott.  The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial , 2012 .